Bausch & Lomb Near Deal to Sell Itself To Valeant For $9 Billion-Report
This article was originally published in PharmAsia News
Executive Summary
Bausch & Lomb Inc. has moved close to a deal to sell itself to drug maker Valeant Pharmaceuticals International Inc. for about $9 billion, the Wall Street Journal reports, citing people familiar with the matter.